Watching Longeveron; Zacks-Small Cap Research Gives $20 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_0192023_LGVN_Sorensen.pdf
Longeveron Shares Surge Following FDA Decision on Biogen Alzheimer’s Drug
Shares of Longeveron (NASDAQ: LGVN) are trading 5.37% higher amid strength in Alzheimer's-related stocks after the FDA granted accelerated approval to Biogen (NASDAQ: BIIB)'s Leqembi. </
Longeveron Provides Corporate Update And Announces 2023 Strategic Priorities And Anticipated Milestones
– Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty in Japan in 1Q23 –
– Extended cash runway into 2H24 –
MIAMI, Jan. 06, 2023 (GLOBE
Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 293 companies set new 52-week lows.
Why Quotient Shares Are Trading Lower By More Than 48%; Here Are 37 Stocks Moving Premarket
Gainers
Netcapital Inc. (NASDAQ: NCPL) shares rose 91.3% to $2.65 in pre-market trading following Q2 results. Netcapital posted Q2 earnings of $0.04 per share on sales of $1.78 million.
Longeveron Granted European Patent Titled ‘METHODS FOR MONITORING EFFICACY OF ALLOGENEIC MESENCHYMAL STEM CELL THERAPY IN A SUBJECT’
https://data.epo.org/publication-server/pdf-document?pn=3221697&ki=B1&cc=EP
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell
• Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
Longeveron Has Been Granted European Patent Number EP3221697 Titled “Methods For Monitoring Efficacy Of Allogeneic Mesenchymal Stem Cell Therapy In A Subject (Related To Its Lomecel-B Lead Therapy Product)”
About this file - European Patent Register (epo.org)
Longeveron’s Return On Capital Employed Insights
Longeveron (NASDAQ:LGVN) brought in sales totaling $466 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 60.23%, resulting in a loss of $5.62 million.